FIND CLINICAL TRIALS

 

TIM-3 = T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN-3

 
 
 

Incyte is developing an antagonistic anti-TIM-3 antibody.

T-cell immunoglobulin and mucin domain-3 (TIM-3) is a co-inhibitory receptor expressed on CD4+ and CD8+ T cells, regulatory T cells (T-regs), and innate immune cells. Multiple ligands exist for TIM-3, including galectin-9, ceacam-1, phosphatidyl serine, and HMGB1. Ligand binding to TIM-3 transmits a negative signal to the cell that promotes immunosuppression.

In cancer, TIM-3 co-expression with PD-1 identifies highly dysfunctional or exhausted tumor-infiltrating effector T cells. In preclinical models, combined inhibition of TIM-3 and PD-1 has been shown to be superior to PD-1 blockade alone at improving T-cell function and suppressing tumor growth.

The therapeutic inhibition of TIM-3 has the potential to improve both cell-mediated and innate immune responses against cancer.

MOLECULE LIBRARY

image show jak target.image of pi3kδ target.image of fgfr target.image of brd target.image of pim target molecule.image of lsd1 target molecule.image shows ido1 target.image shows arg target.image of pd-1 target molecule. image of gitr target molecule. image of ox40 target molecule.  image of Tim-3 target moleculeimage of Lag-3 target moleculeimage of Axr target molecule